These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22429643)

  • 1. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.
    Guzmán Herrador BR; Aavitsland P; Feiring B; Riise Bergsaker MA; Borgen K
    BMC Infect Dis; 2012 Mar; 12():63. PubMed ID: 22429643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.
    Andrews N; Waight P; Yung CF; Miller E
    J Infect Dis; 2011 Jan; 203(1):32-9. PubMed ID: 21148494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
    Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.
    Vesikari T; Richardus JH; Berglund J; Korhonen T; Flodmark CE; Lindstrand A; Silfverdal SA; Bambure V; Caplanusi A; Dieussaert I; Roy-Ghanta S; Vaughn DW
    Pediatr Infect Dis J; 2015 Jul; 34(7):774-82. PubMed ID: 26069949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
    Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
    Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
    Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
    Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination.
    Baum U; Leino T; Gissler M; Kilpi T; Jokinen J
    Vaccine; 2015 Sep; 33(38):4850-7. PubMed ID: 26238723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.
    Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M
    Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.
    Gefenaite G; Tacken M; Bos J; Stirbu-Wagner I; Korevaar JC; Stolk RP; Wolters B; Bijl M; Postma MJ; Wilschut J; Nichol KL; Hak E
    PLoS One; 2013; 8(6):e66125. PubMed ID: 23840413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.
    Lartey S; Pathirana RD; Zhou F; Jul-Larsen Å; Montomoli E; Wood J; Cox RJ
    Hum Vaccin Immunother; 2015; 11(7):1654-62. PubMed ID: 26009966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.
    Wijnans L; Dieleman J; Voordouw B; Sturkenboom M
    PLoS One; 2013; 8(4):e63156. PubMed ID: 23646191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.